Pharyngitis, commonly referred to as a sore throat, is an inflammation of the pharynx often caused by infections like Group A Streptococcus (GAS), which is responsible for 14%-37% of cases in higher-income countries, particularly affecting individuals aged 5-19 years. This disease poses a significant clinical burden, with a high unmet need for improved therapies. Current treatments, such as antibiotics, face limitations, including concerns about resistance and recurrence risks. The growing focus on targeted and innovative therapies, including vaccines and novel antimicrobials, is anticipated to drive advancements in the pharyngitis drug pipeline, addressing the gaps in treatment and improving patient outcomes in the coming years.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pharyngitis.
Pharyngitis treatments mainly include antibiotics for bacterial infections and symptomatic relief for viral cases. Antibiotics like penicillin are used to treat GAS infections, while over-the-counter pain relievers and throat lozenges manage symptoms in viral cases. Despite current treatments, there remains a significant need for more effective therapies to combat recurrent or resistant infections.
This product will be delivered within 3-5 business days.
Report Coverage
The Pharyngitis Drug Pipeline Insight Report by the publisher gives comprehensive insights into pharyngitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pharyngitis. The pharyngitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pharyngitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pharyngitis treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pharyngitis.
Pharyngitis Drug Pipeline Outlook
Pharyngitis (PKU) is an inflammation of the pharynx, typically caused by viral or bacterial infections. Group A Streptococcus (GAS) is a major bacterial cause, with the disease most commonly affecting children aged 5-19. The condition is often triggered by respiratory infections and can lead to significant discomfort and complications if left untreated.Pharyngitis treatments mainly include antibiotics for bacterial infections and symptomatic relief for viral cases. Antibiotics like penicillin are used to treat GAS infections, while over-the-counter pain relievers and throat lozenges manage symptoms in viral cases. Despite current treatments, there remains a significant need for more effective therapies to combat recurrent or resistant infections.
Pharyngitis Epidemiology
Pharyngitis, commonly known as sore throat, is a globally prevalent condition. Acute pharyngitis is a widespread condition leading to approximately 12 million annual ambulatory care visits in the United States, accounting for 1-2% of all ambulatory care visits. Children and adolescents are most affected, with 50% of cases occurring before the age of 18. Adults experience an average of 13.5-14.4 episodes per 100 patient-years, while children face up to 82.5 episodes. Moderate-to-severe pain impacts 70% of patients.Pharyngitis - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of pharyngitis drug candidates based on several segmentations, including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Small Molecules
- Biologics
- Peptides
- Gene Therapy
- Immunomodulators
- Combination Therapies
By Route of Administration
- Oral
- Parenteral
- Others
Pharyngitis - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total pharyngitis clinical trials.Pharyngitis - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the pharyngitis pipeline analysis include small molecules, biologics, peptides, gene therapy, immunomodulators, and combination therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pharyngitis.Pharyngitis Clinical Trials Therapeutic Assessment - Competitive Dynamics
The pharyngitis drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pharyngitis clinical trials:- Dexa Medica
- Genentech Inc.
- Bausch Health Companies Inc.
- Adamas Pharmaceuticals Inc.
- Boehringer Ingelheim
- Pfizer
- Bayer
- Sandoz Pharmaceuticals GmbH
Pharyngitis Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pharyngitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pharyngitis drug candidates.Drug: Phenoxymethylpenicillin
The Phase 4 study is evaluating the effectiveness of phenoxymethylpenicillin versus no antibiotic treatment for Group A Streptococcus-negative sore throat in patients aged 15 and older. The randomized trial, with an estimated enrollment of 260 participants, aims to assess symptom duration and intensity. Completion is anticipated by June 2026.Drug: Qingyan Lihou Decoction
The Chinese University of Hong Kong is sponsoring a Phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Qingyan Lihou Decoction for treating chronic pharyngolaryngitis, a persistent form of pharyngitis. With 74 participants, the study aims to assess symptom relief over an 8-week treatment period, followed by an 8-week post-treatment evaluation.Drug: Benzydamine Hydrochloride
This study aims to evaluate the effectiveness of Benzydamine Hydrochloride spray (Difflam) in reducing postoperative sore throat (POST) after the use of a laryngeal mask airway use. This early phase 1 study, involving 106 participants, is expected to be completed by December 2026. The objective is to assess POST incidence, pain severity, and spray safety in perioperative care.Reasons To Buy This Report
The Pharyngitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pharyngitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into pharyngitis collaborations, regulatory environments, and potential growth opportunities.Key Questions Answered in the Pharyngitis - Pipeline Insight Report
- Which companies/institutions are leading the pharyngitis drug development?
- What is the efficacy and safety profile of pharyngitis pipeline drugs?
- Which company is leading the pharyngitis pipeline development activities?
- What is the current pharyngitis commercial assessment?
- What are the opportunities and challenges present in the pharyngitis drug pipeline landscape?
- What is the efficacy and safety profile of pharyngitis pipeline drugs?
- Which company is conducting major trials for pharyngitis drugs?
- Which companies/institutions are involved in pharyngitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in pharyngitis?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Pharyngitis
4 Patient Profile: Pharyngitis
5 Pharyngitis: Epidemiology Snapshot
6 Pharyngitis: Market Dynamics
7 Pharyngitis: Key Facts Covered
8 Pharyngitis, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Pharyngitis Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Pharyngitis Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Pharyngitis Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Pharyngitis Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Pharyngitis, Key Drug Pipeline Companies